In recent years, there has been a consensus regarding the enhancement of prognosis in patients with advanced non-small cell lung cancer (NSCLC) through the utilization of immune checkpoint inhibitors (ICIs). Numerous clinical studies have also demonstrated the substantial value of immunotherapy for resectable NSCLC patients. Nevertheless, there remain controversies surrounding the exploration of immune combination strategies, treatment-related side effects, prognostic biomarkers, as well as other issues in the neoadjuvant therapy setting. Consequently, this article presents a comprehensive overview of the recent advancements in neoadjuvant immunotherapy for resectable NSCLC, stimulating fresh perspectives and delving into its merits and challenges in clinical application. .
【中文题目：可切除非小细胞肺癌新辅助免疫治疗 研究进展】 【中文摘要：近年来，免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）对晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）患者预后的改善已成为共识，越来越多的临床研究也逐渐证明了免疫治疗对于可切除NSCLC患者的重要价值。然而，目前关于新辅助治疗背景下免疫联合策略的探索、治疗相关副作用、预后生物标志物等问题仍存在争议。本文综述了可切除NSCLC患者新辅助免疫治疗的最新进展，引发了新的思考，并讨论了其在临床应用中的优势及挑战。 】 【中文关键词：肺肿瘤；新辅助治疗；免疫检查点抑制剂；围手术期；可切除非小细胞肺癌】.
Keywords: Immune checkpoint inhibitors; Lung neoplasms; Neoadjuvant therapy; Perioperative period; Resectable non-small cell lung cancer.